Collaboration is the Game
Small patient populations make enrollment and clinical trial design challenging. A rare disease-focused Risk Assessment Categorization Tool (RACT) will help reveal and address orphan drug trial risks more efficiently. Study designs that follow a risk-based strategy, incorporating prognostic and predictive metrics, can significantly increase the amount and quality of data that would help speed up the approval process.
Rare Disease RACT: How Can You Help?
We’re about to launch a new RACT catalog, this time for rare diseases. You can help us optimize the beta version prior to launch. How does it work? We will enable 30-day free access to our clinical trial risk management platform, MyRBQM® Portal. You can either duplicate the Rare Disease RACT within the portal to subsequently edit and optimize it, or you can send your edits and suggestions directly to our Product Manager by email.
Read also: Indication Focused RBQM for Rare Disease Drug Development